An interventional study of Physical activity intervention in Elevated Blood Pressure and Perimenopause, sponsored by The University of Texas Medical Branch, Galveston. Not yet recruiting at 1 site in United States. Open to female participants aged 45 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by The University of Texas Medical Branch, Galveston · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,032 studies in Hypertension with a site in United States — 268 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.
Among the 2,032 studies in Hypertension with a site in United States, this one is the 1,254th largest by planned enrollment of the 1,780 interventional ones that give a count, is one of 18 that started in 2027, is one of 1,072 with no phase, reaches primary completion later than 301 of the 367 other live ones, and was the 1,787th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →268 of the 2,032 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 16–56 · Women only
The University of Texas at Arlington · Sites in United States
Ages 26–49
CRISPR Therapeutics AG · Sites in United States, Australia, United Kingdom
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 45 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,032 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 147 · Phase 2 216 · Phase 3 214 · Phase 4 188
First in 1973; this study’s year is marked. 18 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 100 across the 1,780 interventional studies, 200 across the 238 observational. Of the 1,515 that completed or were terminated, 578 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
461 of 2,032 have an industry lead sponsor. The 10 most frequent:
The University of Texas Medical Branch, Galveston is the lead sponsor of 257 studies on the registry; 36 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
The University of Texas Medical Branch, Galveston has 2 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
144 of the studies in Hypertension with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT04971720Phase 3University of Alabama at BirminghamPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis | 2027-01-01 |
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
Add all 144 to your calendar (.ics) → With an account.
Among the 2,032 studies in Hypertension with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will test the effects of a physical activity intervention among midlife Hispanic women.
The menopausal transition in midlife is a critical juncture where women experience life transitions and adverse physiological and psychological changes that increase the risk for hypertension and cardiovascular diseases in later life. Physical activity improves blood pressure, biomarkers of hypertension, sleep, mood, and well-being; however, Hispanic women meet physical activity recommendations at lower levels than non-Hispanic White women. The investigator will examine the feasibility of the physical activity intervention among sedentary midlife Hispanic women in the menopausal transition with elevated blood pressure, exploring changes in physical activity and health.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Multi-level intervention to increase physical activity
Behavioral: Physical activity intervention
Physical activity
Days the activity monitor was worn
Objectively measured days the wearable activity monitor was worn during the intervention period
Time frame: Baseline to 6-months
Physical activity as measured by minutes of moderate-vigorous intensity physical activity at 6 months
Mean daily minutes of moderate-vigorous intensity physical activity taken from accelerometers for a 7 day period
Time frame: Baseline to 6-months
Physical activity as measured by minutes of moderate-vigorous intensity physical activity at 6 months
Mean daily minutes of moderate-vigorous intensity physical activity taken from accelerometers for a 7 day period
Time frame: Baseline to 12-months
Physical activity as measured by minutes of moderate intensity physical activity at 6 months
Mean daily minutes of moderate intensity physical activity taken from accelerometers for a 7 day period
Time frame: Baseline to 6-months
Physical activity as measured by minutes of moderate intensity physical activity at 6 months
Mean daily minutes of moderate intensity physical activity taken from accelerometers for a 7 day period
Time frame: Baseline to 12-months
Physical activity as measured by minutes of vigorous intensity physical activity at 6 months
Mean daily minutes of vigorous intensity physical activity taken from accelerometers for a 7 day period
Time frame: Baseline to 6-months
Physical activity as measured by minutes of vigorous intensity physical activity at 6 months
Mean daily minutes of vigorous intensity physical activity taken from accelerometers for a 7 day period
Time frame: Baseline to 12-months
Physical activity as measured by minutes of light intensity physical activity at 6 months
Mean daily minutes of light intensity physical activity taken from accelerometers for a 7 day period
Time frame: Baseline to 6-months
Physical activity as measured by minutes of light intensity physical activity at 6 months
Mean daily minutes of light intensity physical activity taken from accelerometers for a 7 day period
Time frame: Baseline to 12-months
Physical activity as measured by minutes of total physical activity at 6 months
Mean daily minutes of total physical activity taken from accelerometers for a 7 day period
Time frame: Baseline to 6-months
Physical activity as measured by minutes of total physical activity at 6 months
Mean daily minutes of total physical activity taken from accelerometers for a 7 day period
Time frame: Baseline to 12-months
Systolic blood pressure
Change in systolic blood pressure (mmHg)
Time frame: Baseline to 6-months
Systolic blood pressure
Change in systolic blood pressure (mmHg)
Time frame: Baseline to 12-months
Diastolic blood pressure
Change in diastolic blood pressure (mmHg)
Time frame: Baseline to 6-months
Diastolic blood pressure
Change in diastolic blood pressure (mmHg)
Time frame: Baseline to 12-months
Abdominal circumference
Change in abdominal circumference (cm)
Time frame: Baseline to 6-months
Abdominal circumference
Change in abdominal circumference (cm)
Time frame: Baseline to 12-months
Body mass index
Change in body mass index (kg/m2)
Time frame: Baseline to 6-months
Body mass index
Change in body mass index (kg/m2)
Time frame: Baseline to 12-months
Plan to share: Yes — The research data from this project will be deposited with a service of the Inter-university Consortium for Political and Social Research (ICPSR), openICPSR, to ensure that the research community has long-term access to the data.
Supporting information: Study protocol, Statistical analysis plan
Time frame: We agree to deposit and/or make available our data upon completion of the clinical trial and acceptance of the data for publication. Data will be stored in the repository for at least 3 years, as required by federal retention guidelines.
Access criteria: Data will be shared via openICPSR as open access.
No publications or documents are linked to this record.
Start is estimated for Apr 2027; primary completion for Jan 2029, 21 months later.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 21 months is close to that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
Start moved once since we started tracking on Sep 25, 2026: Jan 2027 → Apr 2027, on Nov 10, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of Texas Medical Branch, Galveston →